Icariin ameliorates glycolytic dysfunction in Alzheimer's disease models by activating the Wnt/β-catenin signaling pathway

• Published in: The FEBS journal Vol. 291; no. 10; pp. 2221 - 2241
• Main Authors: Liu, Ju, Wei, Ai-Hong, Liu, Ting-Ting, Ji, Xin-Hao, Zhang, Ying, Yan, Fei, Chen, Mei-Xiang, Hu, Jin-Bo, Zhou, Shao-Yu, Shi, Jing-Shan, Jin, Hai, Jin, Feng
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2024
• Subjects: Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Animal models; Animals; beta Catenin - genetics; beta Catenin - metabolism; Catenin; Cell culture; Cell viability; Cognitive ability; Disease Models, Animal; Dkk1 protein; Flavonoids - pharmacology; Glycolysis; Glycolysis - drug effects; Intercellular Signaling Peptides and Proteins - genetics; Intercellular Signaling Peptides and Proteins - metabolism; L-Lactate dehydrogenase; Lactate; Lactate dehydrogenase; Male; Mice; Mice, Transgenic; Neurodegenerative diseases; Neuroprotection; Neuroprotective Agents - pharmacology; Peptide Fragments - metabolism; Proteins; Signal transduction; Western blotting; Wnt protein; Wnt Signaling Pathway - drug effects; icariin; Wnt/β‐catenin signaling pathway; Alzheimer's disease; glycolysis; hexokinase

It was reported that the Wnt/β-catenin pathway is involved in the regulation of aerobic glycolysis and that brain glycolytic dysfunction results in the development of Alzheimer's disease (AD). Icariin (ICA), an active component extracted from Epimedii Folium, has been reported to produce neurop...